塞利尼索(Selinexor) - 药物靶点：ACADS x XPO1_在研适应症：滤泡性淋巴瘤，难治性多发性骨髓瘤，复发性多发性骨髓瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

CRM1-nuclear-export-inhibitor、NEXPOVIO、Selinexor

+ [13]

靶点

ACADS x XPO1

作用方式

抑制剂

作用机制

ACADS inhibitors(acyl-CoA dehydrogenase short chain inhibitors)、XPO1抑制剂(输出蛋白1抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [9]

在研适应症

滤泡性淋巴瘤难治性多发性骨髓瘤复发性多发性骨髓瘤+ [68]

非在研适应症

伴有 FLT3/ITD 突变的急性髓系白血病急性早幼粒细胞白血病前列腺腺癌+ [67]

原研机构

Karyopharm Therapeutics, Inc.

在研机构

德琪医药有限公司

AbbVie, Inc.

Karyopharm Therapeutics, Inc.

+ [13]

非在研机构

The University of Texas MD Anderson Cancer Center

Takeda Pharmaceutical Co., Ltd.

The University of California, San Francisco

+ [1]

权益机构

FORUSTherapeutics, Inc.

德琪（浙江）医药科技有限公司

Foundation Medicine, Inc.

+ [12]

最高研发阶段批准上市

首次获批日期

美国 (2019-07-03),

多发性骨髓瘤

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、附条件批准 (中国)、孤儿药 (韩国)、优先审评 (韩国)、孤儿药 (澳大利亚)、快速通道 (美国)

登录后查看时间轴

结构/序列

分子式C17H11F6N7O

InChIKeyDEVSOMFAQLZNKR-RJRFIUFISA-N

CAS号1393477-72-9

关联

227

项与塞利尼索相关的临床试验

NCT07479979

/ Recruiting临床1/2期IIT

Phase Ib/II Study of Selinexor in Combination With Carfilzomib, Subcutaneous Isatuximab Administered Via Investigational Device and Dexamethasone (SCID) for Patients With Relapsed and/or Relapsed Refractory Multiple Myeloma

The primary objective of this Phase Ib/II trial is to study the safety and tolerability of the combination of selinexor, carfilzomib, isatuximab-OBDS (on body delivery system) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma, who have received at least one line of therapy. The phase Ib portion comprises the safety run-in with 6-12 patients, with the option to reduce the selinexor dose from 40 mg to 20 mg if the higher dose reaches the prescribed toxicity threshold. The Phase II portion of the trial will test the Recommended Phase 2 Dose (RP2D) in an expansion cohort of up to 50 patients.

开始日期2026-07-01

申办/合作机构

Hoosier Cancer Research Network

[+3]

NCT07554482

/ Not yet recruiting临床2期IIT

A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Selinexor Combined With Reduced-Dose Radiotherapy in the Treatment of Early-Stage Extranodal NK/T-Cell Lymphoma

Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus-associated non-Hodgkin lymphoma with high incidence in Asia and Latin America. Approximately 70% of patients present with early-stage (I-II) disease confined to the upper aerodigestive tract. Radiotherapy at 50-56 Gy is the standard curative treatment, but high-dose radiotherapy causes severe toxicities including oral mucositis and xerostomia, while radiotherapy alone yields high systemic recurrence rates. Previous studies have confirmed the efficacy of P-GEMOX induction chemotherapy, verified the feasibility of reduced-dose radiotherapy in patients achieving complete response after chemotherapy, and demonstrated the radiosensitizing effect of selinexor via inhibiting IRF3-BARD1-BRCA1-mediated DNA damage repair. Moreover, international evidence supports the efficacy of 40 Gy radiotherapy combined with chemotherapy. Accordingly, this study hypothesizes that selinexor combined with 40 Gy reduced-dose radiotherapy following P-GEMOX induction chemotherapy can achieve equivalent efficacy to standard-dose radiotherapy, while markedly decreasing radiotherapy-related toxicities. This trial innovatively applies selinexor as a radiosensitizer in ENKTCL, fulfills the unmet clinical demand for efficacy-preserving toxicity reduction, and is well supported by preliminary data.

开始日期2026-05-15

申办/合作机构

首都医科大学附属北京同仁医院

NCT07574528

/ Not yet recruiting临床2期IIT

A Multicenter, Single-Arm, Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma

This is a single-arm, open-label, multicenter phase II study evaluating sintilimab, pegaspargase, and selinexor followed by radiotherapy as first-line treatment for patients with newly diagnosed stage I/II extranodal natural killer/T-cell lymphoma (ENKTL).

开始日期2026-05-06

申办/合作机构

中山大学

100 项与塞利尼索相关的临床结果

登录后查看更多信息

100 项与塞利尼索相关的转化医学

登录后查看更多信息

100 项与塞利尼索相关的专利（医药）

登录后查看更多信息

719

项与塞利尼索相关的文献（医药）

2026-12-31·ANNALS OF MEDICINE

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis

Review

作者: Li, Yuxin ; Sun, Wanling ; Cao, Yaofang ; Hui, Wuhan ; Tan, Shuai

BACKGROUND:

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm. Although Ruxolitinib, a JAK1/2 inhibitor, remains the cornerstone of MF treatment, it does not reverse disease progression, and resistance frequently emerges. These limitations have prompted investigation into combination therapies targeting pathways beyond the JAK-STAT axis. This meta-analysis aims to evaluate the efficacy and safety of Ruxolitinib-based combination therapies in patients with MF.

METHODS:

We conducted a systematic search of databases for studies published through August 1, 2025. Thirteen distinct Ruxolitinib-based combination regimens were included. Primary efficacy endpoints were ≥35% spleen volume reduction at 24 weeks (SVR35) and ≥50% reduction in total symptom score (TSS50). Safety endpoints focused on the incidence of grade 3/4 thrombocytopenia and anemia. Subgroup analyses were performed based on prior JAK inhibitor exposure and therapeutic mechanism of action.

RESULTS:

A total of 19 studies comprising 1,088 patients were included in the meta-analysis. Among JAK inhibitor-naïve patients, the combination of Ruxolitinib with Selinexor demonstrated the highest efficacy (SVR35: 92%; TSS50: 78%), followed by Ruxolitinib plus BMS-986158 (SVR35: 90%). For patients with prior JAK inhibitor exposure, Ruxolitinib plus Siremadlin (SVR35: 45%) showed notable activity.

CONCLUSION:

For JAK inhibitor-naïve patients, Ruxolitinib-based combination regimens demonstrated satisfactory clinical responses and the potential for meaningful disease control. For patients with prior JAK inhibitor exposure, the addition of combination therapy drugs may further enhance the efficacy. Personalized treatment selection remains essential, as therapeutic efficacy is significantly influenced by prior JAK inhibitor exposure.

2026-12-31·Hematology

XPO1 inhibitor selinexor suppresses homologous recombination by inhibiting E2F7 nuclear export in acute myeloid leukemia

Article

作者: Wang, Dandan ; Xu, Chunli ; Chen, Yu ; Feng, Xu ; Chen, Ruiqi ; Cheng, Feng

OBJECTIVES:

Aberrant nucleocytoplasmic transport mediated by Exportin 1 (XPO1) contributes to leukemogenesis, yet the molecular basis underlying the limited efficacy of the XPO1 inhibitor Selinexor in acute myeloid leukemia (AML) remains unclear. This study aimed to define the role of XPO1 in AML and elucidate the mechanism by which Selinexor regulates homologous recombination (HR).

METHODS:

Public AML datasets and patient samples were analyzed to assess XPO1 expression and clinical relevance. Functional assays evaluated the effects of XPO1 knockdown on AML cell proliferation, apoptosis, and cell cycle progression. Transcriptomic analysis, immunoprecipitation, subcellular fractionation, DNA damage assays, and direct HR functional assays were used to investigate Selinexor-mediated mechanisms. Drug interaction analyses assessed the combined effect of Selinexor and Mitoxantrone.

RESULTS:

XPO1 was significantly overexpressed in AML, particularly in relapsed cases, and high expression was associated with poor prognosis. XPO1 knockdown suppressed proliferation, induced apoptosis, and caused cell cycle arrest. High XPO1 expression correlated with activation of the HR pathway. Mechanistically, Selinexor disrupted the interaction between XPO1 and the transcriptional repressor E2F7, resulting in nuclear retention of E2F7 and downregulation of BRCA1 and RAD51. E2F7 silencing reversed Selinexor-induced HR suppression and DNA damage. In addition, Selinexor synergized with Mitoxantrone to enhance DNA damage and apoptosis in AML cells.

DISCUSSION:

E2F7-mediated HR inhibition is a key mechanism underlying Selinexor activity in AML.

CONCLUSION:

The XPO1-E2F7-HR axis represents a potential therapeutic vulnerability, supporting the rational combination of Selinexor with DNA-damaging agents to improve AML treatment outcomes.

2026-06-01·BIOORGANIC CHEMISTRY

PET imaging of XPO1 engagement with [18F]selinexor: A pharmacodynamic theranostic strategy for multiple myeloma

Article

作者: Yan, Junjie ; Pan, Donghui ; Su, Chen ; Wang, Lizhen ; Zhong, Xinlin ; Yang, Min ; Wang, Xinyu ; Xu, Yuping ; Chen, Chongyang

Exportin 1 (XPO1), a nuclear export protein frequently overexpressed in multiple myeloma (MM), represents a validated therapeutic target. However, noninvasive imaging approaches capable of assessing XPO1 engagement and pharmacodynamic modulation during therapy remain limited. Here, we present the radiosynthesis and preclinical evaluation of [¹⁸F]selinexor, an XPO1-targeted positron emission tomography (PET) radiotracer derived from the clinically used drug selinexor via an ¹⁸F/¹⁹F isotope exchange method. This labeling approach preserves the parent drug's molecular structure and pharmacological characteristics, enabling in vivo tracking of selinexor. [¹⁸F]Selinexor was synthesized with a radiochemical yield of 23.9 ± 4.1% and molar activity of 0.41 ± 0.08 GBq/μmol. The tracer exhibited favorable stability, XPO1-specific binding, and tumor retention. PET imaging and pharmacokinetic analysis demonstrated rapid systemic distribution followed by slow elimination, closely consistent with known pharmacokinetics of selinexor. Predominant hepatobiliary clearance and prolonged blood retention supported optimal tumor uptake at delayed imaging time points, with tracer uptake peaking at 3 h post-injection in MM.1S (2.92 ± 0.30% ID/g) and NCI-H929 (2.50 ± 0.18% ID/g) xenografts. Uptake was markedly reduced upon blocking, confirming the tracer's in vivo specificity. During therapeutic intervention, repeated selinexor administration effectively suppressed tumor growth and was accompanied by a progressive reduction in tumor uptake from 3.03 ± 0.25% ID/g (day 0) to 0.93 ± 0.13% ID/g (day 15). Notably, this reduction in uptake occurred independently of changes in tumor volume and correlated with decreased XPO1 expression by immunohistochemistry. Conversely, doxorubicin reduced tumor size without affecting uptake, indicating preserved XPO1-associated signal. Together, these findings demonstrate that [¹⁸F]selinexor PET functions as a noninvasive imaging tool for evaluating the in vivo pharmacokinetics and pharmacodynamic behavior of selinexor, and capturing treatment-induced alterations in XPO1 engagement, although further structural optimization will be required prior to potential translation.

805

项与塞利尼索相关的新闻（医药）

2026-06-01

·PRNewswire

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 1,200 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of May 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. About Karyopharm Therapeutics Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit and follow Karyopharm on LinkedIn and on X at @Karyopharm. XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. SOURCE Karyopharm Therapeutics Inc. 21% more press release views with Request a Demo

上市批准快速通道加速审批

2026-06-01

·PRNewswire

Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial – – Conference Call Scheduled for Tuesday, June 2, 2026 at 2:00 p.m. ET – NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will host a conference call on June 2, 2026 at 2:00 p.m. ET featuring the Company's senior management team and Dr. John Mascarenhas, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders, and principal investigator of the Phase 3 SENTRY trial. The call will discuss the results from the Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis and will follow Dr. Mascarenhas' oral presentation of the results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, . An archived webcast will be available on the Company's website approximately two hours after the event. About Karyopharm Therapeutics Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit and follow Karyopharm on LinkedIn and on X at @Karyopharm. XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. SOURCE Karyopharm Therapeutics Inc. 21% more press release views with Request a Demo

临床3期上市批准ASCO会议

2026-06-01

·手机新浪网

必贝特涨5.11%，成交额1.69亿元，后市是否有机会？

6月1日，必贝特涨5.11%，成交额1.69亿元，换手率9.30%，总市值154.68亿元。异动分析细胞免疫治疗+科创次新股+减肥药+创新药+注册制次新股1、根据招股说明书：截至本招股说明书签署日，国内已获批用于三线及以上治疗 r/r DLBCL 的药物为复星凯特引进的阿基仑赛注射液（Yescarta）、药明巨诺的瑞基奥仑赛注射液、罗氏制药的格菲妥单抗注射液（Columvi）、德琪医药引进的 Selinexor（塞利尼索片，XPOVIO，一种核输出抑制剂）、ADC Therapeutics 和瓴路药业联合申报的注射用替朗妥昔单抗、必贝特的BEBT-908（注射用盐酸伊吡诺司他）和上海恒润达生生物的雷尼基奥仑赛注射液，阿基仑赛注射液、瑞基奥仑赛注射液和雷尼基奥仑赛注射液均为 CAR-T 疗法。2、广州必贝特医药股份有限公司于2025-10-28上市，公司主营业务为创新药物的研发、生产和销售。3、根据招股说明书：在研产品中，BEBT-808 是公司自主研发的一种口服小分子 GLP-1R 完全激动剂，用于治疗糖尿病和肥胖症，预计将于 2025 年提交临床试验申请。BEBT-809 是First-in-Class GPR75 通路抑制剂，用于治疗肥胖症，预计将于 2025 年提交临床试验申请。BEBT-701 为全球首个治疗高脂血症合并高血压的双靶点 siRNA 药物，预计将于 2025 年提交临床试验申请。4、广州必贝特医药股份有限公司主营业务是创新药物的研发、生产和销售。主要产品是小分子双靶点抑制剂。5、广州必贝特医药股份有限公司于2025-10-28日上市，主营业务为创新药物的研发、生产和销售。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入104.65万，占比0.01%，行业排名45/158，该股当前无连续增减仓现象，主力趋势不明显；所属行业主力净流入-5.74亿，当前无连续增减仓现象，主力趋势不明显。区间今日近3日近5日近10日近20日主力净流入104.65万-1982.66万-3233.56万-5184.49万-2644.14万主力持仓主力没有控盘，筹码分布非常分散，主力成交额3859.02万，占总成交额的5.19%。技术面：筹码平均交易成本为35.25元该股筹码平均交易成本为35.25元，近期筹码快速出逃，建议调仓换股；目前股价靠近支撑位34.20，注意支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。公司简介资料显示，广州必贝特医药股份有限公司位于广东省广州市高新技术产业开发区科学城崖鹰石路25号A-3栋第七层、第八层，成立日期2012年1月19日，上市日期2025年10月28日，公司主营业务涉及创新药自主研发。必贝特所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌药物、抗癌治癌、生物医药、减肥药、细胞免疫治疗等。截至5月20日，必贝特股东户数1.13万，较上期减少1.75%；人均流通股4731股，较上期增加1.78%。2026年1月-3月，必贝特实现营业收入0.00元；归母净利润-5273.57万元，同比减少45.49%。机构持仓方面，截止2026年3月31日，必贝特十大流通股东中，易方达医疗保健行业混合A（110023）位居第一大流通股东，持股212.76万股，相比上期增加141.99万股。博时天颐债券A（050023）位居第三大流通股东，持股112.42万股，为新进股东。长城消费增值混合A（200006）位居第七大流通股东，持股80.42万股，为新进股东。华宝生态中国混合A（000612）位居第八大流通股东，持股44.47万股，为新进股东。大摩健康产业混合A（002708）位居第九大流通股东，持股37.77万股，为新进股东。东方红医疗升级股票发起A（015052）、广发创新医疗两年持有期混合A（010731）、招商医药健康产业股票（000960）、交银医药创新股票A（004075）、广发沪港深医药混合A（014114）、东方红医疗创新混合(QDII)A（025070）、广发睿智两年持有期混合发起式A（013616）、招商前沿医疗保健股票A（011373）、融通中国风1号灵活配置混合A/B（001852）退出十大流通股东之列。

100 项与塞利尼索相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11222	塞利尼索	L01XX66	DB11942

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
滤泡性淋巴瘤	印尼	德琪医药有限公司	2025-03-05
难治性多发性骨髓瘤	中国	Karyopharm Therapeutics, Inc.	2021-12-14
复发性多发性骨髓瘤	中国	Karyopharm Therapeutics, Inc.	2021-12-14
复发性弥漫性大B细胞淋巴瘤	以色列	Karyopharm Therapeutics, Inc.	2021-02-04
难治性弥漫性大 B 细胞淋巴瘤	以色列	Karyopharm Therapeutics, Inc.	2021-02-04
弥漫性大B细胞淋巴瘤	美国	Karyopharm Therapeutics, Inc.	2020-06-22
多发性骨髓瘤	美国	Karyopharm Therapeutics, Inc.	2019-07-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性急性髓细胞白血病	临床3期	中国	德琪医药有限公司	2023-01-29
复发性急性髓细胞白血病	临床3期	中国	德琪医药有限公司	2023-01-29
子宫内膜癌	临床3期	中国	Karyopharm Therapeutics, Inc.	2021-10-27
子宫内膜癌	临床3期	中国	德琪医药有限公司	2021-10-27
真性红细胞增多症后骨髓纤维化	临床3期	美国	Karyopharm Therapeutics, Inc.	2021-03-11
真性红细胞增多症后骨髓纤维化	临床3期	澳大利亚	Karyopharm Therapeutics, Inc.	2021-03-11
真性红细胞增多症后骨髓纤维化	临床3期	比利时	Karyopharm Therapeutics, Inc.	2021-03-11
真性红细胞增多症后骨髓纤维化	临床3期	保加利亚	Karyopharm Therapeutics, Inc.	2021-03-11
真性红细胞增多症后骨髓纤维化	临床3期	加拿大	Karyopharm Therapeutics, Inc.	2021-03-11
真性红细胞增多症后骨髓纤维化	临床3期	捷克	Karyopharm Therapeutics, Inc.	2021-03-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04925193 (CTgov)	临床2期	复发性多发性骨髓瘤	18	Carfilzomib+Daratumumab+Dexamethasone+Selinexor+pomalidomide	艱鬱醖衊鑰艱齋蓋選繭 = 衊壓壓簾壓鬱衊鹽簾鹽憲醖鏇繭艱鹹齋廠膚遞 (齋網衊獵遞簾構遞憲構, 憲鹹衊構夢鹹淵鏇壓鹹 ~ 觸壓網鹹齋鹹餘憲願齋) 更多	-	2026-03-06
NCT04856189 (CTgov)	临床1/2期	晚期尿路上皮癌 \| 局部晚期尿路上皮癌 \| 转移性尿路上皮癌	4	Selinexor+Pembrolizumab	獵顧築鑰艱遞範遞選糧 = 壓選衊夢壓遞醖範簾淵鑰艱願鏇鹹鏇簾艱餘醖 (醖襯窪觸糧壓網願願憲, 選醖淵壓積鑰顧顧遞鹽 ~ 鹹鑰窪獵構簾廠願艱鹹) 更多	-	2026-01-29
NCT04595994 (Pubmed \| Nat Commun)	临床1期	肉瘤	17	Gemcitabine + Selinexor	衊鏇壓鬱廠艱蓋顧糧簾(觸構鏇窪鹹選餘鬱積範) = gemcitabine at 1200 mg/m2 at 10 mg/m2/min followed by 60 mg weekly selinexor 築窪鏇艱鏇醖鑰遞壓遞 (製鹹餘齋鑰鹹願顧醖齋 ) 更多	积极	2026-01-20
ASH2025	N/A	复发性弥漫性大B细胞淋巴瘤	54	Selinexor-based regimens bridging CAR-T cell therapy	獵壓築襯積齋製鏇廠窪(膚糧糧獵網觸網鏇夢艱) = Grade 1 occurred in 9 patients (60%) and 28 patients (71.8%), respectively; Grade 2 in 1 patient (6.7%) and 4 patients (10.3%); Only one patient in the selinexor-based regimen group experienced Grade 4 (6.7%) CRS. There is no difference between the selinexor-based group and alternative regimen groups (grade 1-4: 73.3% vs 82.1% p=0.475; grade 3 and 4: 6.7% vs 0%; p=0.278). 願鏇遞範膚繭網築獵願 (膚構壓鑰鏇衊範鹹蓋願 ) 更多	积极	2025-12-06
ASH2025	N/A	复发性弥漫性大B细胞淋巴瘤	54	Alternative regimen bridging CAR-T cell therapy		积极	2025-12-06
NCT06517511 (Smart trial, ASH2025)	临床2期	TP53突变弥漫性大B细胞淋巴瘤一线 TP53 mutations	11	Selinexor plus R-CHOP	艱築鏇醖餘積鹹遞觸艱(顧獵蓋製觸艱齋艱觸願) = 齋觸齋遞醖艱膚壓築蓋獵壓繭蓋鹹觸憲鏇觸壓 (製膚遞糧鑰鹹艱衊蓋餘 ) 更多	积极	2025-12-06
NCT05422027 (ASH2025)	临床1/2期	多发性骨髓瘤一线	21	Selinexor + Bortezomib + Lenalidomide + Dexamethasone	夢憲鬱艱壓窪醖襯夢獵(憲醖襯獵築製衊衊齋鹹) = 範遞醖簾製蓋廠憲繭獵蓋蓋鹽艱遞築憲網顧顧 (廠廠壓壓鏇簾觸遞遞襯 ) 更多	积极	2025-12-06
ASH2025	临床1/2期	骨髓增生异常综合征 TP53	39	Selinexor sequential azacytidine (TP53 mutations)	鬱憲簾鹽淵選製構艱範(選繭壓鏇夢齋顧願憲艱) = 廠觸製憲鏇廠築齋鬱糧窪壓鹹鏇觸蓋窪鹹襯遞 (襯糧醖鬱衊繭遞衊蓋齋 ) 更多	积极	2025-12-06
NCT02343042 (STOMP, ASH2025)	临床1期	复发性多发性骨髓瘤	13	Selinexor 40 mg + mezigdomide 0.6 mg + dexamethasone 40 mg	夢觸網製製觸齋艱鑰膚(糧網積廠糧繭襯廠獵鏇) = As of July 8, 2025, no dose-limiting toxicities (DLTs) were encountered in cohorts 1 and 2. Two DLTs occurred in cohort 3. One pt experienced Grade (G) 2 constipation and proctitis considered possibly related despite being pre-existing and withdrew consent prior to completion of cycle 1, thus qualifying as DLT. Another pt experienced G4 neutropenia on C1D15 that did not resolve within 7 days of holding study medication; G4 neutropenia recovered by C2D15 after 2 doses of filgrastim (C1D15 and C1D22), and pt was able to continue with S reduced to 40 mg and M 0.6 mg. 簾壓夢構餘廠製糧襯齋 (觸遞衊鏇醖築齋範網繭 ) 更多	积极	2025-12-06
SEALAND (ASH2025)	临床3期	多发性骨髓瘤维持	149	Selinexor+Lenalidomide	蓋夢範衊簾艱積淵積願(齋遞願齋餘簾鹹壓餘窪) = 衊鑰範鏇窪鬱餘醖鏇餘鏇醖願醖廠餘積製簾遞 (壓繭獵窪淵鬱衊願艱蓋 ) 更多	不佳	2025-12-06
SEALAND (ASH2025)	临床3期	多发性骨髓瘤维持	149	Lenalidomide	蓋夢範衊簾艱積淵積願(齋遞願齋餘簾鹹壓餘窪) = 積淵範鏇簾觸鹹簾餘願鏇醖願醖廠餘積製簾遞 (壓繭獵窪淵鬱衊願艱蓋 ) 更多	不佳	2025-12-06
SABLe (ASH2025)	临床2期	多发性骨髓瘤一线	47	Selinexor-dexamethasone with alternating lenalidomide and bortezomib	鑰鏇觸範糧淵願鏇餘淵(製膚糧簾餘膚糧憲鹹餘) = 膚構積鹽網選觸遞窪淵鏇齋餘築廠構膚範簾鏇 (壓艱窪壓憲餘獵醖壓膚 ) 更多	积极	2025-12-06